Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Acquires Global Rights to CDK2 Inhibitor from Ensem in $1.3 Billion Deal

publication date: Nov 21, 2023

Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem says it discovers cryptic pockets of traditionally undruggable targets to discover candidates for difficult-to-drug targets. CDK2, which is critical to cell cycle regulation, is often hyper-activated in cancers, causing abnormal cancer cell growth. There are no approved CDK2 therapies anywhere. BeiGene said the candidate, ETX-197, is close to filing an IND to treat some breast cancers. Ensem will receive an upfront payment plus milestones and royalties, though specific details were not disclosed. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here